2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的探索与评价

doi:10.19803/j.1672-8629.20220559

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (3): 273-276.
DOI: 10.19803/j.1672-8629.20220559

2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的探索与评价

王姗¹, 黄举凯¹, 吴宏辉¹, 温雅璐¹, 张力², 王建华³, 杨晓晖^1,*

¹北京中医药大学东直门医院肾病内分泌二区,北京 100700;
²北京中医药大学东方医院科研处,北京 100078;
³首都儿科研究所,北京 100020

收稿日期:2022-09-22 出版日期:2023-03-15 发布日期:2023-03-17
通讯作者: ^* 杨晓晖,男,主任医师·博导,内分泌系统疾病中医临床与基础研究。E-mail:yxh0616@126.com
作者简介:王姗,女,博士,内分泌系统疾病中医临床与基础研究。
基金资助:
国家自然科学基金资助项目(81974541)

Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease

WANG Shan¹, HUANG Jukai¹, WU Honghui¹, WEN Yalu¹, ZHANG Li², WANG Jianhua³, YANG Xiaohui^1,*

¹Department of Nephrology and Endocrinology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China;
²Scientific Research Department, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078, China;
³Capital Institute of Pediatrics, Beijing 100020, China

Received:2022-09-22 Online:2023-03-15 Published:2023-03-17

摘要/Abstract

摘要： 目的探索2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的年龄节点和稳定性。方法 12周龄C57BL/6J小鼠18只作为对照组,普通饲料喂养;KKAy小鼠18只作为模型组,高脂饲料喂养。对照组和模型组分别于14、18、22周龄各随机处死6只小鼠,检测血糖、体重、肝功、血脂等指标,观察病理学形态改变情况。结果与对照组相比,自14周龄起,模型组小鼠体重、肝重、肝重指数、血糖水平显著增加（P< 0. 05）,模型组血糖水平符合糖尿病改变。血清学结果显示,与对照组相比,模型组小鼠的谷丙转氨酶（ALT）、谷草转氨酶（AST）、胆固醇（CHOL）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）水平显著升高（P<0.05）,2组小鼠甘油三酯（TG）水平未形成显著性差异（P>0.05）。病理染色显示,14周龄模型组小鼠存在肝细胞脂肪变性,22周龄出现炎性细胞浸润。结论 14周龄KKAy小鼠经高脂饮食诱导可作为研究2型糖尿病合并非酒精性脂肪性肝病稳定的动物模型。

关键词: 2型糖尿病, 非酒精性脂肪性肝病, KKAy小鼠, 动物模型

Abstract: Objective To explore the age of onset and stability of a KKAY animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease. Methods Eighteen twelve-week-old C57BL/6J mice were assigned to the control group that was fed with normal diets while another 18 twelve-week-old KKAy mice served as the model group that was fed with high-fat diets. Six mice in control and model group were randomly killed at the 14,18,22 weeks of age, respectively. Blood glucose, weight, serum liver function and lipid levels were monitored and the pathological changes of hepatic tissues were observed. Results Compared with the control group, the body mass, liver mass, liver index and blood glucose level of the model group increased significantly (P< 0.05) from the 14th week. The results of serology showed that the ALT, AST, CHOL, HDL-C and LDL-C levels were significantly increased compared with the control group (P< 0.05), but no significant difference was found in TG levels between the two groups (P> 0.05). Pathological staining showed both steatosis of hepatocytes in the 14th week and inflammatory cell infiltration in the 22nd week. Conclusion The 14-week-old KKAy mice treated with high fat diets can serve as a stable mouse model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease.

Key words: type 2 diabetes mellitus, nonalcoholic fatty liver disease, KKAy mice, animal model

中图分类号:

R965.1

王姗, 黄举凯, 吴宏辉, 温雅璐, 张力, 王建华, 杨晓晖. 2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的探索与评价[J]. 中国药物警戒, 2023, 20(3): 273-276.

WANG Shan, HUANG Jukai, WU Honghui, WEN Yalu, ZHANG Li, WANG Jianhua, YANG Xiaohui. Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 273-276.

参考文献

[1] HAZLEHURST JM, WOODS C, MARJOT T, et al.Non-alcoholic fatty liver disease and diabetes[J]. Metabolism, 2016, 65(8): 1096-1108.
[2] RHEE EJ.Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective[J]. Endocrinol Metab (Seoul), 2019, 34(3): 226-233.
[3] DEWIDAR B, KAHL S, PAFILI K, et al.Metabolic liver disease in diabetes - From mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299.
[4] LEI L, HUAN Y, SUN SJ, et al.Novel specific peroxisome proliferator-activated receptorγ modulator YR4-42 corrects metabolic abnormalities and nonalcoholic fatty liver in type 2 diabetic KKAy mice[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(11): 1544-1548.
[5] ZHU HW, LI H, HAO F, et al.Liraglutide may reduce lipid metabolism in mice with type 2 diabetes and non-alcoholic fatty liver through AMPK pathway[J].Diabetes New World(糖尿病新世界), 2021, 24(18): 50-52,56.
[6] YI Q.Experimental study of rhodiola crenulata extract on NAFL and exploration of NASH mouse model[D]. Beijing: Peking Union Medical College, 2017.
[7] ZHANG XL, WANG YN, MA LY, et al.Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway[J]. Acta Pharmacol Sin, 2020, 41(3): 383-393.
[8] QIN Y, PUYANG S, JUAN L, et al.Rho, a fraction from rhodiola crenulate, ameliorates hepatic steatosis in mice models[J]. Front Physiol,2018,9:222.
[9] YKI-JARVINEN H.Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 901-910.
[10] YOUNOSSI ZM, GOLABI P, AVILA LD, et al.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
[11] ROHM TV, MEIER DT, OLEFSKY JM, et al.Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022, 55(1): 31-55.
[12] JAHN D, KIRCHER S, HERMANNS HM, et al.Animal models of NAFLD from a hepatologist’s point of view[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 943-953.
[13] WANG B, CHANDRASEKERA PC, PIPPIN JJ.Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes[J]. Curr Diabetes Rev, 2014, 10(2): 131-145.
[14] SUN G, JACKSON CV, ZIMMERMAN K, et al.The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose[J]. BMC Gastroenterol, 2019, 19(1): 41.
[15] MACHADO MV, MICHELOTTI GA, XIE G, et al.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease[J]. PLoS One, 2015, 10(6): e0132315.
[16] MA Y, LI J, JU Z, et al.Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway[J]. J Ethnopharmacol, 2021, 279: 114320-114329.
[17] LI X, WANG TX, HUANG X, et al.Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity[J]. Liver Int, 2020, 40(6): 1378-1394.
[18] FURMAN BL.Streptozotocin-induced diabetic models in mice and rats[J]. Curr Protoc, 2021, 1(4): e78.
[19] FUJII M, SHIBAZAKI Y, WAKAMATSU K, et al.A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J]. Med Mol Morphol, 2013, 46(3): 141-152.
[20] YAN D, LI SY, WEI YY.Study on establishment of animal model with diabetes complicated fatty liver induced by streptozocin and nicotinamide[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2015, 31(18): 1846-1848.
[21] YAMAMOTO T, YAMAGUCHI H, MIKI H, et al.Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets[J]. Eur J Pharmacol, 2010, 640(1-3): 243-249.
[22] YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
[23] BYRNE CD, TARGHER G.NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64.
[24] AAGHARPOUR A, CAZANAVE SC, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]. J Hepatol, 2016, 65(3): 579-588.
[25] LOU JL, WANG Q, YANG S, et al.Hepatic injury in diabetic KKAY mice[J].Chinese Journal of Cellular and Molecular Immunology(细胞与分子免疫学杂志), 2008(9): 902-903.
[26] ESLAM M, VALENTI L, ROMEO S.Genetics and epigenetics of NAFLD and NASH: clinical impact[J]. J Hepatol, 2018, 68(2): 268-279.
[27] SONG YL, HUANG JK, CONG JL, et al.Establishment of an animal model of diabetic gastroparesis[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(4): 341-345.

2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的探索与评价

Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[2]	包蕾, 耿子涵, 郭姗姗, 姚荣妹, 孙静, 崔晓兰. 热炎宁合剂对呼吸系统感染性炎症动物抗感染作用研究[J]. 中国药物警戒, 2023, 20(3): 241-247.
[3]	高敬, 张卓, 闫佳怡, 葛运炫, 马增春, 高月. 高原气虚血瘀证动物模型评价及治疗药物研究进展[J]. 中国药物警戒, 2023, 20(10): 1189-1194.
[4]	庞博, 张敬升, 郭姗姗, 孙静, 包蕾, 徐英莉, 曹姗, 陈梦苹, 王雅欣, 赵荣华, 崔晓兰. 人冠状病毒229E湿热疫毒袭肺病证结合小鼠模型的建立及评价[J]. 中国药物警戒, 2023, 20(1): 40-45.
[5]	穆思聪, 王卓, 卢俊阳, 纪立伟, 柳鑫. 吡格列酮对2型糖尿病患者血浆脂联素影响的Meta分析[J]. 中国药物警戒, 2022, 19(9): 1015-1018.
[6]	杨柳, 石凤华, 马丽娟. 基于Logistic回归分析格列美脲不良反应影响因素及其对治疗2型糖尿病有效性的影响[J]. 中国药物警戒, 2022, 19(9): 1030-1034.
[7]	黄瑛, 侯田田, 秦超, 霍艳, 王三龙, 文海若, 耿兴超. 嵌合抗原受体T细胞产品非临床安全性评价内容和主要关注的问题探讨[J]. 中国药物警戒, 2022, 19(8): 813-816.
[8]	向玉芳, 孙辉, 陈月, 王宁生, 罗世书, 张智, 冯变玲. 2型糖尿病降糖药不良反应及联合用药情况分析[J]. 中国药物警戒, 2022, 19(3): 313-316.
[9]	宋亚玲, 黄举凯, 丛佳林, 程淑莉, 张力, 杨晓晖. 糖尿病胃轻瘫动物模型建立方法初探[J]. 中国药物警戒, 2021, 18(4): 341-345.
[10]	陈琪莹, 黄丹丹, 陈添玉. 高剂量卡格列净对2型糖尿病安全性的Meta分析[J]. 中国药物警戒, 2021, 18(2): 150-154.
[11]	戚仁娟, 撒小军, 宋洁, 张永明. 甘精胰岛素与阿卡波糖分别联合二甲双胍对2型糖尿病患者长期血糖控制对比分析[J]. 中国药物警戒, 2018, 15(12): 709-712.
[12]	窦立雯, 孙蓉. 肝纤维化动物模型研究进展与中药药效评价应用概况[J]. 中国药物警戒, 2017, 14(3): 179-182.
[13]	潘凤珍,张平,张金梅. 院内外延伸药学服务对2型糖尿病患者治疗效果及不良反应发生率的影响[J]. 中国药物警戒, 2017, 14(12): 764-768.
[14]	冯静, 郑虎林. 硫辛酸注射液对糖尿病脑梗塞患者疗效及血清炎性因子的影响[J]. 中国药物警戒, 2016, 13(6): 330-332.
[15]	孙晓倩，孙蓉. 中药抗脂肪肝活性发现与药效评价的动物模型应用概况与研制思路[J]. 中国药物警戒, 2016, 13(2): 90-93.